Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma

Abstract Objective To investigate whether dose reductions in cisplatin due to renal dysfunction were associated with worse clinical outcomes in metastatic urothelial carcinoma (UC) patients. Patients and methods One hundred and fifty one metastatic UC patients who received first‐line gemcitabine plu...

Full description

Bibliographic Details
Main Authors: Tetsushi Murakami, Eiji Kikuchi, Hiroki Ide, Yuta Umezawa, Takayuki Takahashi, Mizuki Izawa, Kyohei Hakozaki, Keisuke Shigeta, Koichiro Ogihara, Hiroaki Kobayashi, Kunimitsu Kanai, Takahiro Maeda, Shunsuke Yoshimine, Ryuichi Mizuno, Koshiro Nishimoto, Mototsugu Oya
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:BJUI Compass
Subjects:
cisplatin‐unfit
GC
metastatic urothelial carcinoma
renal failure
salvage chemotherapy
Online Access:https://doi.org/10.1002/bco2.81

Internet

https://doi.org/10.1002/bco2.81

Similar Items